Cereno Sci­en­tif­ic de­tails mid-stage re­sults for pul­monary ar­te­r­i­al hy­per­ten­sion drug

Cereno Sci­en­tif­ic’s HDAC in­hibitor hit the pri­ma­ry end­point of safe­ty and tol­er­a­bil­i­ty in a Phase 2a tri­al in pa­tients with pul­monary ar­te­r­i­al hy­per­ten­sion, send­ing its …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER